As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’
Yeah, but then you have packaging costs, and distribution costs, and marketing costs, and shareholder dividends, and CEO bonuses, and AI integration, and lobbying costs…
So really, we’re practically losing money at a $450/month subscription.
Yeah, but then you have packaging costs, and distribution costs, and marketing costs, and shareholder dividends, and CEO bonuses, and AI integration, and lobbying costs…
So really, we’re practically losing money at a $450/month subscription.
$450/mo. would be a bargain. They’ll be squeezing them for hundreds of thousands a year.